Rbf Capital, LLC Allakos Inc. Transaction History

Rbf Capital, LLC

$1.96 Billion
Q3 2024

A detailed history of Rbf Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Rbf Capital, LLC holds 510,529 shares of ALLK stock, worth $541,160. This represents 0.02% of its overall portfolio holdings.

Number of Shares

510,529

Previous 350,000 45.87%

Holding current value

$541,160

Previous $350,000 5.43%

% of portfolio

0.02%

Previous 0.02%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.92 $86,685 - $147,686	160,529 Added 45.87%	510,529 $331,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.45 $350,000 - $507,500	350,000 New	350,000 $350,000
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $563,453 - $1.14 Million	-186,574 Reduced 65.13%	99,900 $611,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $183,835 - $434,134	-70,706 Reduced 19.8%	286,474 $897,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $176,230 - $340,318	-34,691 Reduced 8.85%	357,180 $2.03 Million
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $3.35 Million - $43.8 Million	391,871 New	391,871 $3.84 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.

Account